Dupixent's already a blockbuster, but there's much more to come: Sanofi exec

Dupixent is on track to deliver about €2 billion in annual sales, but Sanofi execs say they're still in the early stages of the launch. The company is investing globally to support the rollout in atopic dermatitis, its original indication, and as it wins new uses in key markets.